Vutriciran市场规模、份额和成长分析（按药物类别、给药途径、患者人群、通路和地区划分）－2026-2033年产业预测

预计到 2024 年，全球维曲康市场规模将达到 4.96 亿美元，到 2025 年将成长至 5.585 亿美元，到 2033 年将成长至 14.432 亿美元，在预测期（2026-2033 年）内复合年增长率为 12.6%。

全球vutrisiran市场经历了显着成长，这主要得益于其创新的RNA干扰机制。此机制能够有效降低转甲状腺素蛋白水平，从而治疗遗传性和野生型ATTR类淀粉沉积症样变性。这项治疗前景已促使其在主要市场获得监管部门核准，并拓展了其在心肌病领域的适应症。诊断检测意识的提高、疾病盛行率的上升以及研发投入的增加，进一步推动了市场扩张。然而，高昂的治疗费用和每季给药的需求等挑战依然存在，限制了患者的用药，尤其是在低收入地区。此外，医保覆盖范围的严格审查、由于疾病认知度低导致的漏诊、专科医生短缺以及缺乏长期安全性数据等因素，都阻碍了其作为一线治疗方案的普及，进而影响了整体市场战略和增长潜力。

全球Vutricilane市场驱动因素

全球vutrisiran市场的主要驱动因素是遗传性转甲状腺素类淀粉沉积症样变性（hATTR）盛行率的不断上升。 hATTR是一种罕见且进行性疾病，会导致全身性淀粉样蛋白沉积，并涉及多个器官。医疗专业人员和患者对hATTR的认识不断提高，推动了对有效治疗方法的需求，其中包括vutrisiran。 vutrisiran透过RNA干扰提供了一种全新的治疗方法。此外，诊断技术的进步使得早期检测成为可能，从而实现及时治疗性介入。人们对个人化医疗的日益关注以及对改善患者预后的重视，进一步推动了人们对vutrisiran作为一种变革性治疗方案的兴趣。

全球Vutricilane市场的限制因素

全球vutrisiran市场面临的主要限制因素是药物上市前必须经过严格的监管核准流程。这些旨在确保药物安全性和有效性的严格法规，可能导致研发週期延长和生产成本增加。此外，所需的临床试验也十分复杂，尤其对于资源有限的新兴企业，更是如此。这种环境可能会抑制创新，阻碍新进业者开发vutrisiran相关治疗方法，最终阻碍市场成长，并使相关疾病患者难以获得这种治疗选择。

全球Vutricilane市场趋势

受RNAi疗法持续进步的推动，全球vutrisiran市场正经历显着成长。这些进步包括RNAi药物递送系统的改进、疗效的提升以及安全性的提高，使其成为治疗遗传性疾病（例如遗传性ATTR类淀粉沉积症变性）的有效选择。随着vutrisiran继续引领这一创新治疗领域，人们对RNAi技术的兴趣和投资日益增长，这为更广泛的应用铺平了道路，并建立了强大的治疗方案研发管线。科学进步与临床疗效的融合预计将显着扩大vutrisiran市场，反映出RNAi作为变革性医疗保健方法的日益受到认可。

目录

介绍

• 调查目标
• 市场定义和范围

调查方法

• 调查过程
• 二手资料和一手资料方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争格局概述

市场动态与展望

• 总体经济指标
• 驱动因素和机会
• 限制与挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

关键市场考察

• 关键成功因素
• 影响市场的因素
• 关键投资机会
• 生态系测绘
• 市场吸引力指数（2025）
• PESTEL 分析
• 价值链分析
• 定价分析
• 案例研究
• 监管环境
• 技术评估

全球Vutriciran市场规模（按药物类别和复合年增长率划分）（2026-2033年）

• 反义寡核苷酸
  • 单链反义寡核苷酸
  • 双链反义寡核苷酸
• 核酸
  • 基于DNA的核酸
  • 基于RNA的核酸
• 核苷酸
  • 嘌呤核苷酸
  • 嘧啶核苷酸
• 核苷
  • 嘌呤核苷
  • 嘧啶核苷
• 其他药物类别

全球Vutriciran市场规模（依给药途径及复合年增长率划分）（2026-2033年）

• 口服
• 注射
• 皮下注射

全球Vutriciran市场规模（按患者群体划分）及复合年增长率（2026-2033年）

• 儿童
• 成人
• 老年人

全球Vutricilane市场规模（依通路划分）及复合年增长率（2026-2033年）

• 医院药房
• 零售药房
• 网路药房
• 其他分销管道

全球 Vutricilane 市场规模（按地区划分）及复合年增长率（2026-2033 年）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Alnylam Pharmaceuticals, Inc.
• Blackstone Life Sciences
• Medison Pharma
• Regeneron Pharmaceuticals, Inc.
• Roche（F. Hoffmann-La Roche Ltd）
• Novartis AG
• Sanofi SA
• Pfizer Inc.
• BridgeBio Pharma, Inc.
• Ionis Pharmaceuticals, Inc.
• AstraZeneca
• Fujifilm Diosynth Biotechnologies
• Thermo Fisher Scientific（Patheon）
• Catalent, Inc.
• Lonza Group AG
• Samsung Biologics
• WuXi Biologics
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.（MSD）
• Noble Pharma Co., Ltd.

结论与建议

Global Vutrisiran Market size was valued at USD 496.0 million in 2024 and is poised to grow from USD 558.5 million in 2025 to USD 1443.2 million by 2033, growing at a CAGR of 12.6% during the forecast period (2026-2033).

The global vutrisiran market is experiencing significant growth, fueled by its innovative RNA interference mechanism that effectively lowers transthyretin protein levels, addressing both hereditary and wild-type ATTR amyloidosis. This therapeutic promise has led to regulatory approvals across key markets and expanded usage to include cardiomyopathy. Enhanced awareness of diagnostic testing, a rising prevalence of the disease, and increased R&D investment further support market expansion. However, challenges persist, including high treatment costs and quarterly administration, which restrict patient access, particularly in lower-income regions. Additionally, stringent payer scrutiny over coverage, underdiagnosis due to low disease awareness, a shortage of specialized clinicians, and limited long-term safety data hinder its acceptance as a first-line therapy, affecting overall market strategies and growth potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vutrisiran market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vutrisiran Market Segments Analysis

Global Vutrisiran Market is segmented by Drug Class, Route of Administration, Patient Demographics, Distribution Channel and region. Based on Drug Class, the market is segmented into Antisense Oligonucleotide, Nucleic Acids, Nucleotide, Nucleoside and Other Drug Classes. Based on Route of Administration, the market is segmented into Oral, Injectable and Subcutaneous. Based on Patient Demographics, the market is segmented into Pediatric, Adult and Geriatric. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Vutrisiran Market

A key market driver for the global Vutrisiran market is the increasing prevalence of hereditary transthyretin-mediated amyloidosis (hATTR), a rare and progressive disease causing systemic amyloid deposits that affect multiple organs. As awareness of hATTR grows among healthcare professionals and patients, there is a rising demand for effective therapies, notably Vutrisiran, which offers a novel approach to managing the disease through RNA interference. Additionally, advancements in diagnostic techniques facilitate earlier detection, leading to timely treatment interventions. The growing focus on personalized medicine and improved patient outcomes further propels the interest in Vutrisiran as a transformative therapeutic option.

Restraints in the Global Vutrisiran Market

A significant market restraint for the global Vutrisiran market is the rigorous regulatory approval processes that pharmaceutical products must undergo before reaching the market. These stringent regulations, designed to ensure drug safety and efficacy, can lead to prolonged development timelines and increased costs for manufacturers. Additionally, the complexity of the clinical trials required can pose challenges, particularly for emerging companies with limited resources. This environment may discourage innovation and deter new entrants from pursuing Vutrisiran-related treatments, ultimately hindering market growth and access to this therapeutic option for patients suffering from related conditions.

Market Trends of the Global Vutrisiran Market

The global Vutrisiran market is experiencing significant growth, driven by ongoing advancements in RNAi therapeutics. This trend encompasses enhanced delivery systems, increased potency, and improved safety profiles of RNAi drugs, making them effective options for treating genetic disorders such as hereditary ATTR amyloidosis. As Vutrisiran continues to lead the way in this innovative treatment landscape, increased interest and investment in RNAi technologies are opening pathways for broader applications, establishing a robust pipeline of therapeutic solutions. The convergence of scientific progress and clinical efficacy positions the Vutrisiran market for substantial expansion, reflecting a growing recognition of RNAi as a transformative approach in medicine.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment

Global Vutrisiran Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Antisense Oligonucleotide
  • Single-Stranded Antisense Oligonucleotides
  • Double-Stranded Antisense Oligonucleotides
• Nucleic Acids
  • DNA-based Nucleic Acids
  • RNA-based Nucleic Acids
• Nucleotide
  • Purine Nucleotides
  • Pyrimidine Nucleotides
• Nucleoside
  • Purine Nucleosides
  • Pyrimidine Nucleosides
• Other Drug Classes

Global Vutrisiran Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Subcutaneous

Global Vutrisiran Market Size by Patient Demographics & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult
• Geriatric

Global Vutrisiran Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels

Global Vutrisiran Market Size & CAGR (2026-2033)

• North America (Drug Class, Route of Administration, Patient Demographics, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Route of Administration, Patient Demographics, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Route of Administration, Patient Demographics, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Route of Administration, Patient Demographics, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Route of Administration, Patient Demographics, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Alnylam Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Blackstone Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medison Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (F. Hoffmann-La Roche Ltd)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BridgeBio Pharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Diosynth Biotechnologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (Patheon)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (MSD)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Noble Pharma Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations